Open in interactive viewer → charts, metric popovers & call review

Zealand Pharma's Four-Asset Metabolism: The Balance Sheet Became the Story

Q3 2026 marked the quarter Zealand stopped sounding like a one-molecule obesity biotech and started sounding like a self-funded platform—just as analysts began asking what it will do with the cash.
ZEAL.CO · Earnings Call · 2026-11-12

The story changed before the numbers did

On 12 November 2026, Zealand Pharma's Q3 call opened with a sentence that would have been hard to imagine a year earlier. Adam Steensberg did not lead with petrelintide's weight-loss percentage. He led with a strategy: Metabolic Frontier 2030. The quarter, he said, “showed what it looks like in motion.” — Adam Steensberg, Chief Executive Officer (CEO) · 2026-11-12 The motion is real: four late-stage assets, a positive EU opinion in short bowel syndrome, a completed cardiovascular safety trial for survodutide, and a cash balance that flips the funding question on its head. The old Zealand story was tolerability versus GLP-1s. The new one is a multi-asset platform with a balance sheet. The financial engine is now the headline. Revenue for the first nine months was DKK 4.5 billion, driven by the Roche collaboration: a DKK 3.7 billion Phase III initiation milestone and a DKK 798 million first-anniversary milestone. The company delivered a DKK 3.5 billion profit and ended September with DKK 13.5 billion of cash. That is not a biotech scraping together a Phase III budget. It is a company that can fund its share of the Roche partnership and still invest in early research.

Due to the initiation of the phase III, we will receive the $575 million cash milestone from Roche, which is partly offset by a $175 million payment for the contribution of enicepatide to the petrelintide/enicepatide combination. That is net $400 million in cash, corresponding to approximately DKK 2.6 billion that we will receive in the fourth quarter.

Henriette Wennicke, Chief Financial Officer (CFO) · 2026-11-12
The buyback is the tell. In August 2025, Steensberg was categorical: “You should not expect a share buyback program from Zealand.” — Adam Sinding Steensberg, Chief Executive Officer · 2025-08-14 By Q3 2026, Zealand had completed DKK 1.2 billion of buybacks after the Roche Phase III decision. On this call, CFO Henriette Wennicke left the door only slightly ajar: “no commitments on additional share buybacks for you today.” — Henriette Wennicke, Chief Financial Officer (CFO) · 2026-11-12 That is a capital-allocation pivot, not a permanent policy. It says the board is willing to return cash when the partnership de-risks a milestone, but it is not yet treating the balance sheet as excess capital. Guidance for operating expenses was narrowed to DKK 2.7–3.0 billion, which management framed as cost control rather than a slowdown. Analysts, naturally, asked whether the lower end reflected efficiency or delayed trials; Wennicke declined to break it out.

From amylin monotherapy to multimodality

The keyword record shows the shift cleanly. In prior quarters, Zealand's language was dominated by petrelintide monotherapy, dose escalation, product profile, amylin analog, and foundational therapy. Those ideas are still present, but the current quarter's top keywords include collaboration with Generate Biomedicines, a Cambridge research hub, Kv1.3 ion channel blocker, rare disease, Boehringer Ingelheim, and cardiovascular safety. This is not sector boilerplate. It is a company-specific expansion of the investment case. Utpal Singh put it plainly: “In less than a year, we have become a multimodality metabolic health company.” — Utpal Singh, Executive/Management · 2026-11-12 That matters because it changes the terminal value. Zealand is no longer just a royalty stream on petrelintide plus a profit share with Roche. It is trying to build a discovery engine that spans peptides, small molecules, biologics, and conjugates, with Cambridge as a second research site and Generate as an AI-protein partner. The company still expects the first wave of preclinical candidates from this strategy soon, and it reiterated the ambition of more than 10 clinical programs by 2030. Whether that ambition is credible is a separate question, but the narrative has widened. The obesity language is more ambiguous. High weight loss remains the company's top keyword, yet management spent part of the Q&A distancing itself from the number. “We need to move away from the weight loss Olympics and start to think about the specific weight losses that an individual patient need.” — Adam Steensberg, Chief Executive Officer (CEO) · 2026-11-12 That phrase is not new—it was coined on the February 2026 call—but it now sits alongside a combination strategy. Petrelintide is being positioned as the tolerability-first monotherapy; the combination of petrelintide with Roche's enicepatide is for patients who need the highest weight loss. The Phase II ZYNERGY trial is expected to start in Q4 2026. Management would not guide on when data will arrive, which is sensible for a partnered study but leaves the market without a near-term catalyst.

Rare disease and immunology are no longer sidebars

The positive CHMP opinion for glepaglutide is the most concrete near-term value driver. In Phase III, 66% of short bowel syndrome patients achieved a clinical response versus 39% on placebo, and 14% treated with Zeydovio were weaned off parenteral support versus none on placebo. The product is a twice-weekly auto-injector, which would make it the first ready-to-use GLP-2. Zealand is running EASE-5 to support a U.S. NDA and is in partnership discussions. Adam Steensberg said the preference is “a global partnership for the asset,” — Adam Steensberg, Chief Executive Officer (CEO) · 2026-11-12 though regional deals remain possible. The market opportunity is described as north of $1 billion today, with room to expand if a better-tolerated GLP-2 changes prescribing. Kv1.3 is the wildcard. ZP9830 is in Phase Ib in plaque psoriasis after positive multiple-ascending-dose data, and management estimates the target could apply across more than 80 autoimmune diseases affecting roughly 8% of the U.S. population. That is a pipeline-in-a-product claim, and it invites skepticism. But it is also a genuinely new leg of the story. Steensberg suggested partnering could come earlier rather than later: “partnering somewhat earlier rather than later could be an interesting opportunity for Zealand.” — Adam Steensberg, Chief Executive Officer (CEO) · 2026-11-12 If that happens, it would validate the Cambridge/Generate expansion beyond metabolic disease.

What management would not answer

The Q&A was polite but persistent. Analysts asked for the total development spend ahead for the petrelintide franchise; Wennicke declined. They asked whether ZYNERGY could produce a 2027 data cut; Steensberg said “It is too early to guide on when you can expect data.” — Adam Steensberg, Chief Executive Officer (CEO) · 2026-11-12 They asked whether another buyback is coming; no commitment. They asked how Zealand weighs a glepaglutide deal now versus waiting for EASE-5; management said it will choose the right partner at the right time. None of this is evasive in a partnership context, but it does mean the near-term story rests on Roche and Boehringer execution rather than Zealand-controlled catalysts. Survodutide is the other underappreciated leg. Boehringer's SYNCHRONIZE-CVOT met its primary endpoint with a hazard ratio of 0.89 versus placebo, and Boehringer is moving toward global regulatory submissions in obesity in 2027. Zealand has EUR 315 million of outstanding regulatory and commercial milestones plus high-single-to-low-double-digit royalties. The caveat is tolerability: GI discontinuations were higher on survodutide in the older protocol, mostly during dose escalation, which the newer Phase III-B trials are designed to address. The market will watch whether flexible titration closes that gap. If it does, Boehringer Ingelheim could turn survodutide into a broader cardiometabolic franchise, with MASH data from LIVERAGE expected in 2027. The tension in the stock—and in the story—is that Zealand now has more shots on goal but fewer near-term proofs. The balance sheet removes financing risk. The Roche partnership removes Phase III execution risk on petrelintide, at least partly. The CHMP opinion gives glepaglutide a real approval path. But the company is also asking investors to underwrite a multimodality research engine whose output will not be visible for years. The prior call's promise was that Zealand would “definitely expect to move into Phase Three with a partner.” — Adam Steensberg, Chief Executive Officer · 2025-02-20 That promise was kept. The next promise—five launches by 2030—is a much longer put. For now, the quarter's most important message is not a weight-loss number. It is that Zealand has become a company that can pay for its own ambitions. The market may still trade it on petrelintide's next data point, but management is clearly trying to change the benchmark.